63 citations as recorded by crossref.

1. External Validation of the Joint-Specific Bone Involvement, Antimicrobial Options, Coverage of the Soft Tissues, and Host Status (JS-BACH) Classification for Predicting Outcome in Periprosthetic Joint Infections: A Cohort of 653 Patients N. Kristensen et al. 10.1016/j.arth.2024.03.070
2. Interleukin-1β Polymorphisms Are Genetic Markers of Susceptibility to Periprosthetic Joint Infection in Total Hip and Knee Arthroplasty V. Granata et al. 10.3390/genes15050596
3. Patient mortality after total hip arthroplasty revision surgery G. Jayasinghe et al. 10.1016/j.jor.2023.11.020
4. Delayed Diagnosis of Mycobacterium bovis Bacillus Calmette-Guérin Periprosthetic Joint Infection Following Total Knee Arthroplasty C. Pelt et al. 10.1016/j.artd.2024.101350
5. Single-stage revision in the management of prosthetic joint infections after total knee arthroplasty – A review of current concepts T. Pradhan et al. 10.1016/j.jcot.2024.102431
6. Surfaces Containing Sharp Nanostructures Enhance Antibiotic Efficacy R. Bright et al. 10.1021/acs.nanolett.2c02182
7. High Mortality After Total Knee Arthroplasty Periprosthetic Joint Infection is Related to Preoperative Morbidity and the Disease Process but Not Treatment N. Drain et al. 10.1016/j.arth.2022.03.046
8. Early Periprosthetic Joint Infections in Total Hip and Knee Arthroplasty: Microorganisms, Mortality, and Implant Survival Using a Combined Dataset From the Dutch Arthroplasty Register and the Dutch National Nosocomial Surveillance Network M. van Veghel et al. 10.1016/j.arth.2024.07.019
9. Should All Patients Receive Extended Oral Antibiotic Prophylaxis? Defining Its Role in Patients Undergoing Primary and Aseptic Revision Total Joint Arthroplasty K. Bundschuh et al. 10.1016/j.arth.2024.01.012
10. Trends in Extended Oral Antibiotic Prophylaxis Utilization Following Primary and Revision Total Hip Arthroplasty From 2010 to 2022 A. Zhao et al. 10.1016/j.arth.2024.01.016
11. The value of sonication on orthopaedic implants in an everyday clinical setting – an exploratory study D. Ponraj et al. 10.1186/s12891-023-06796-x
12. Intrawound Vancomycin Powder in Primary Total Hip Arthroplasty: A Prospective Quality Control Study S. Doxey et al. 10.1016/j.arth.2024.03.063
13. “Once more, with feeling”: no difference in outcomes between patients discharged on oral versus intravenous antibiotics for orthopedic infections in a propensity score matched cohort at a US medical center J. Gray et al. 10.1017/ash.2024.57
14. Timing-specific Debridement, Antibiotics, and Implant Retention and 2-Stage Revision for Megaprosthesis-Related Infection: Optimizing the Window Period for Improved Outcomes R. Sharma et al. 10.1016/j.artd.2025.101688
15. Staphylococcus epidermidis joint isolates: Whole-genome sequencing demonstrates evidence of hospital transmission and common antimicrobial resistance S. Simon et al. 10.1017/ice.2023.253
16. Are Patient-Reported Drug Allergies Associated With Prosthetic Joint Infections and Functional Outcomes Following Total Hip and Knee Arthroplasty? N. Fisher et al. 10.1016/j.arth.2021.09.008
17. Improve Integration of In Vitro Biofilm Body of Knowledge to Support Clinical Breakthroughs in Surgical Site Infection S. Irwin et al. 10.5435/JAAOSGlobal-D-20-00217
18. Modern Microbiological Methods to Detect Biofilm Formation in Orthopedy and Suggestions for Antibiotic Therapy, with Particular Emphasis on Prosthetic Joint Infection (PJI) P. Mikziński et al. 10.3390/microorganisms12061198
19. The CCJR® Charles A. Engh, Sr, MD. Excellence in Hip Research Award: The Evolution of Revision Hip Arthroplasty and Impact on the Trainee’s Experience S. Muscatelli et al. 10.1016/j.arth.2024.03.003
20. Treating Hepatitis C Prior to Total Hip Arthroplasty is Cost-effective: A Markov Analysis A. Anoushiravani et al. 10.1016/j.arth.2023.02.067
21. Outcomes of Debridement, Antibiotics, and Implant Retention in the Management of Infected Total Knee Arthroplasty: Analysis of 5,178 Cases From the National Australian Registry N. Kristensen et al. 10.1016/j.arth.2024.12.016
22. Increased short- and long-term mortality amongst patients with early periprosthetic knee joint infection O. Thompson et al. 10.1186/s12891-022-06024-y
23. Simultaneous Periprosthetic Joint Infection and Infective Endocarditis: Prevalence, Risk Factors, and Clinical Presentation M. Held et al. 10.1016/j.arth.2024.09.034
24. A novel strategy for eradication of staphylococcal biofilms using blood clots K. Grooters et al. 10.3389/fcimb.2025.1507486
25. A novel process to reduce the cost of admission for treatment of infected shoulder arthroplasty J. Harley et al. 10.1016/j.jse.2025.02.028
26. Much higher re-revision rates and mortality following septic revision total knee arthroplasty compared to meta-analyses L. Becker et al. 10.1302/0301-620X.107B9.BJJ-2024-1440.R1
27. Similar Efficacy and Lower Cost Associated With Ceftazidime Compared to Tobramycin Coupled With Vancomycin in Antibiotic Spacers in the Treatment of Periprosthetic Joint Infection D. Lewis et al. 10.1016/j.arth.2024.04.018
28. Insight into antibacterial effect of titanium nanotubular surfaces with focus on Staphylococcus aureus and Pseudomonas aeruginosa J. Šístková et al. 10.1038/s41598-024-68266-1
29. Mid-term follow-up results after implementing a new strategy for the diagnosis and management of periprosthetic joint infections R. Birlutiu et al. 10.1186/s12879-021-06407-x
30. Risk factors for mortality following one-stage septic hip arthroplasty — a case–control study S. Busch et al. 10.1007/s00264-021-05230-y
31. Biofilm and How It Relates to Prosthetic Joint Infection A. MacConnell et al. 10.1016/j.ocl.2023.10.001
32. Increased Mortality Following Periprosthetic Joint Infection After Total Hip Arthroplasty: A Microbiologically Verified Nationwide Cohort of 1,611 PJI Revisions N. Kristensen et al. 10.1016/j.arth.2025.06.011
33. Triaging Total Hip Arthroplasty During the COVID-19 Pandemic J. Rizkalla et al. 10.1007/s12178-020-09642-y
34. An in silico testbed for fast and accurate MR labeling of orthopedic implants G. Noetscher et al. 10.7554/eLife.90440
35. Middle-term two-stage treatment results of fistulous and non-fistulous form of chronic hip periprosthetic joint infection A. Kochish et al. 10.17816/vto633949
36. Tissue niche influences immune and metabolic profiles to Staphylococcus aureus biofilm infection Z. Van Roy et al. 10.1038/s41467-024-53353-8
37. Increased Mortality Following Periprosthetic Joint Infection After Total Knee Arthroplasty: A Microbiologically Verified Nationwide Cohort of 916 Cases N. Kristensen et al. 10.1016/j.arth.2025.05.117
38. Detailed Revision Risk Analysis after Single- vs. Two-Stage Revision Total Knee Arthroplasty in Periprosthetic Joint Infection: A Retrospective Tertiary Center Analysis L. Tuecking et al. 10.3390/antibiotics10101177
39. Approach to patients with a potential prosthetic joint infection B. Atkin et al. 10.1136/bmj-2021-069502
40. Fifteen-Year Mortality Following Periprosthetic Joint Infection in Total Knee Arthroplasty N. Kristensen et al. 10.2106/JBJS.24.01630
41. An in silico testbed for fast and accurate MR labeling of orthopedic implants G. Noetscher et al. 10.7554/eLife.90440.3
42. Molecular sequencing technologies in the diagnosis and management of prosthetic joint infections Z. Gamie et al. 10.1080/14737159.2021.1894929
43. The AAHKS Clinical Research Award: Extended Oral Antibiotics Prevent Periprosthetic Joint Infection in High-Risk Cases: 3855 Patients With 1-Year Follow-Up M. Kheir et al. 10.1016/j.arth.2021.01.051
44. The Investigation and Management of Peri-Prosthetic Joint Infection After Total Knee Arthroplasty: An Update Based on the Latest British Orthopaedic Association Standard and Speciality Standard Guidelines S. Doski et al. 10.7759/cureus.73315
45. Long-Term Mortality Associated with Periprosthetic Infection in Total Hip Arthroplasty D. Campbell et al. 10.2106/JBJS.24.01629
46. Cefazolin Is Associated With a Lower Periprosthetic Joint Infection Risk than Alternative Antibiotic Regimens Following Total Hip Arthroplasty B. Carter et al. 10.1016/j.arth.2025.04.079
47. Prevention of Prosthetic Joint Infection: From Traditional Approaches towards Quality Improvement and Data Mining J. Gallo & E. Nieslanikova 10.3390/jcm9072190
48. Acute kidney injury in the context of staged revision arthroplasty and the use of antibiotic-laden cement spacers: a systematic review Y. Chaudhry et al. 10.1186/s13018-023-03809-2
49. What are the risk factors and microorganism profiles of periprosthetic hip joint infections with a concomitant sinus tract? M. Budin et al. 10.1007/s00402-024-05713-8
50. Periprosthetic Joint Infection: A Multifaceted Burden Undermining Arthroplasty Success M. Aftab et al. 10.52965/001c.138205
51. Outcomes of Staphylococcal Prosthetic Joint Infection After Hip Hemiarthroplasty: Single Center Retrospective Study A. Mahmoud et al. 10.3390/medicina61040602
52. Antibiotic Therapy for Prosthetic Joint Infections: An Overview B. Le Vavasseur & V. Zeller 10.3390/antibiotics11040486
53. Comparison of Five-Day vs. Fourteen-Day Incubation of Cultures for Diagnosis of Periprosthetic Joint Infection in Hip Arthroplasty C. Baez et al. 10.3390/jcm13154467
54. External Validation Demonstrates Limited Clinical Utility of a Preoperative Prognostic Calculator for Periprosthetic Joint Infection R. Monárrez et al. 10.1016/j.arth.2021.02.067
55. Prevalence and Factors Associated with Prosthetic Joint Infections in Patients with Staphylococcus aureus Bacteraemia: A 7-Year Retrospective Study M. Papadimitriou-Olivgeris et al. 10.3390/antibiotics11101323
56. Biofilms—What Should the Orthopedic Surgeon know? M. Dhillon et al. 10.1007/s43465-022-00782-6
57. Diagnosis of orthopaedic-implant-associated infections caused by slow-growing Gram-positive anaerobic bacteria – a clinical perspective D. Ponraj et al. 10.5194/jbji-6-367-2021
58. Assessment of sonication-based culture in diagnosing orthopedic implant infections: a comparative analysis with microbiological diagnostic approaches Y. ÇEKLİ & D. EGE 10.32322/jhsm.1361635
59. Projections and Epidemiology of Revision Hip and Knee Arthroplasty in the United States to 2030 A. Schwartz et al. 10.1016/j.arth.2020.02.030
60. Risk Factors for Therapeutic Failure and One-Year Mortality in Patients with Intramedullary Nail-Associated Infection after Trochanteric and Subtrochanteric Hip Fracture Repair B. Pfang et al. 10.3390/antibiotics13050463
61. Does Treatment at a Specialized Prosthetic Joint Infection Center Improve the Rate of Reimplantation T. Fehring et al. 10.1016/j.arth.2023.03.082
62. Does Vancomycin Resistance Increase Mortality? Clinical Outcomes and Predictive Factors for Mortality in Patients with Enterococcus faecium Infections J. Hemapanpairoa et al. 10.3390/antibiotics10020105
63. Short-term outcomes of articular cement spacer in the treatment of prosthetic knee joint infections: a retrospective case series P. Yeo et al. 10.4103/singaporemedj.SMJ-2021-389